Learn more about GEA Pharma Systems' revolutionary Consigma™ continuous high-shear granulation, drying and tableting system at P-MEC India 2009. The system satisfies the pharmaceutical industry’s demand for continuous production to provide improved quality, flexibility and consistency for pharmaceutical processes.

One Consigma™ can run 500g in R&D, but can also run clinical trial, launch size, and any production size batches. There is no process scale-up as time is the only relevant factor in a continuous process. This allows manufacturers to reduce development time dramatically to reduce costs and bring products to market much faster.

Compact, modular construction with very short installation time
The system is light weight, ultra small (1/3 of a classic granulation line - inclusive of tablet press) and has a modular construction making it fit perfectly in any R&D department or an existing tablet production room. There’s no need to change the building, just wheel it in, connect the power and air supply, and after a simple start-up period it’s ready to go. Installation time and cost are reduced to a fraction of the current benchmark.

Consistent granule quality with improved compressibility characteristics
Consigma™ is capable of doing particle design and mimicking any traditional batch granulation process - with a much higher and consistent quality resulting from its continuous production set up and ‘risk based approach’ to GMP. The granules have generally a better intra-granular porosity with better compressibility characteristics that help tablet presses run more efficiently, at maximum speed with hardly any weight adjustments required.